Jim Cramer says this former Covid market darling is finally investable again

CNBC’s Jim Cramer said Moderna has moved beyond its Covid-era business, pointing to an expanding pipeline of treatments for cancer and other diseases as the core long-term thesis. He cautioned that the most promising programs are still years from commercialization, but indicated he would buy shares on weakness. Net message: modestly positive outlook focused on pipeline-driven fundamentals rather than near-term earnings.

Analysis

The market problem for MRNA is not whether the platform can work in theory; it is whether investors will finance a multi-year proof cycle without visible commercial offsets. A “buy weakness” framing can help the stock in the near term by shifting attention from shrinking legacy revenue to pipeline optionality, but that only supports multiple expansion if upcoming clinical updates are credible enough to reduce the probability-weighted cash burn overhang. In other words, the stock can trade like a biotech option only if the next few readouts start to look monetizable; otherwise it remains a de-rating candidate as the COVID-era base disappears.

Second-order, this is more important for peer perception than for direct competitive share. A cleaner pipeline narrative would support sentiment across platform biotechs and mRNA-adjacent names, while a failure to convert science into late-stage data would reinforce the market’s preference for nearer-term earnings and push capital toward larger, cash-generative pharma or better-diversified biotech ETFs like XBI/IBB. The hidden risk is that “long-term story” stocks often underperform after the first enthusiasm spike because the market demands proof, not optionality, and discounts years of R&D expense at a higher rate as rates stay elevated.

The contrarian view is that the move may be over-optimistic if investors assume the platform re-rate happens automatically. What would actually falsify the bullish thesis is not generic skepticism, but slippage in trial timelines, weaker-than-expected efficacy/safety signals, or cash burn that forces a tighter capital allocation framework before the pipeline matures. Over 1-3 months, the stock likely trades on commentary and sector beta; over 6-18 months, it trades on whether management can translate platform breadth into at least one visible commercial winner.

Key Decisions for Investors

• No immediate chase: treat MRNA as a watchlist name, not a momentum long, unless the next catalyst cycle includes a material clinical/data event that can change estimates rather than sentiment.
• If you want exposure, express it as a small starter long in MRNA versus short XBI for 3-6 months: this isolates idiosyncratic pipeline re-rating while hedging broad biotech tape risk; thesis breaks if sector beta turns sharply risk-on.
• Use any 1-2 day strength from commentary-driven buying to sell covered calls or fade into strength; the risk/reward is poor if the market is only paying for narrative and not near-term EPS/cash-flow support.
• For a more convex expression, consider a 6-12 month call spread in MRNA only if you have a defined upcoming readout window; without a catalyst, implied carry and decay are likely to dominate.
• Set alerts for pipeline readout timing and cash-burn guidance; if management pushes milestones out materially or operating expense guidance rises faster than expected, downgrade the thesis quickly.